Management of motor complications in parkinson disease: Current and emerging therapies

Neurologic Clinics

Volumn 28, Issue 4, 2010, Pages 913-925

  Espay, Alberto J ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Dyskinesias; Motor complications; Motor fluctuations; Parkinson disease

Indexed keywords

ACR 325; AFQ 056; AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOMPERIDONE; ENTACAPONE; FIPAMEZOLE; LEVODOPA; LISURIDE; METHYLPHENIDATE; NEU 120; NP 002; PICLOZOTAN; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SARIZOTAN; SCH 420814; SELEGILINE; TOLCAPONE; TRIMETHOBENZAMIDE; UNCLASSIFIED DRUG;

ANKLE EDEMA; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COGNITIVE DEFECT; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DYSKINESIA; EDEMA; GAIT; GASTROINTESTINAL TOXICITY; HALLUCINATION; HEPATITIS; HUMAN; IMPULSE CONTROL DISORDER; LIVEDO RETICULARIS; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK REDUCTION; SOMNOLENCE; VOMITING;

DEEP BRAIN STIMULATION; DOPAMINE AGONISTS; DYSKINESIAS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 77956255079     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2010.03.014     Document Type: Review

References (51)

1. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol 1996, 39(1):37-45.
2. Friedman A. Levodopa-induced dyskinesia: clinical observations. J Neurol 1985, 232(1):29-31.
3. Wagner M.L., Fedak M.N., Sage J.I., et al. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Ann Clin Lab Sci 1996, 26(5):389-395.
4. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16(3):448-458.
5. Marsden C.D., Parkes J.D., Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. Movement disorders 1982, 96-122. Butterworth, London. C.D. Marsden, S. Fahn (Eds.).
6. Blanchet P.J., Allard P., Gregoire L., et al. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996, 23(3):189-193.
7. Marras C., Lang A., Krahn M., et al. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 2004, 19(1):22-28.
8. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001, 56(11 Suppl 5):S1-S88.
9. Metman L.V., Del D.P., LePoole K., et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999, 56(11):1383-1386.
10. Snow B.J., Macdonald L., Mcauley D., et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000, 23(2):82-85.
11. Luginger E., Wenning G.K., Bosch S., et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000, 15(5):873-878.
12. Thomas A., Iacono D., Luciano A.L., et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004, 75(1):141-143.
13. Cummings J.L. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991, 39(7):708-716.
14. Durif F., Debilly B., Galitzky M., et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004, 62(3):381-388.
15. Fabbrini G., Brotchie J.M., Grandas F., et al. Levodopa-induced dyskinesias. Mov Disord 2007, 22(10):1379-1389.
16. Hauser R.A., Shulman L.M., Trugman J.M., et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008, 23(15):2177-2185.
17. Goetz C.G., Damier P., Hicking C., et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007, 22(2):179-186.
18. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005, 62(2):241-248.
19. Rascol O., Brooks D.J., Melamed E., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005, 365(9463):947-954.
20. Dewey R.B., Hutton J.T., LeWitt P.A., et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001, 58(9):1385-1392.
21. Giladi N., McDermott M.P., Fahn S., et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001, 56(12):1712-1721.
22. Garcia Ruiz P.J., Meseguer E., Del Val J., et al. Motor complications in Parkinson disease: a prospective follow-up study. Clin Neuropharmacol 2004, 27(2):49-52.
23. Krystkowiak P., Blatt J.L., Bourriez J.L., et al. Effects of subthalamic nucleus stimulation and levodopa treatment on gait abnormalities in Parkinson disease. Arch Neurol 2003, 60(1):80-84.
24. Mizuno Y., Kondo T., Mori H. Various aspects of motor fluctuations and their management in Parkinson's disease. Neurology 1994, 44(7 Suppl 6):S29-S34.
25. Auriel E., Hausdorff J.M., Herman T., et al. Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study. Clin Neuropharmacol 2006, 29(1):15-17.
26. Devos D., Krystkowiak P., Clement F., et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007, 78(5):470-475.
27. Nutt J.G., Carter J.H., Sexton G.J. The dopamine transporter: importance in Parkinson's disease. Ann Neurol 2004, 55(6):766-773.
28. Keating G.M., McClellan K., Jarvis B. Methylphenidate (OROS formulation). CNS Drugs 2001, 15(6):495-500.
29. Giladi N. Medical treatment of freezing of gait. Mov Disord 2008, 23(Suppl 2):S482-S488.
30. Lim I., van Wegen E., de Goede C., et al. Effects of external rhythmical cueing on gait in patients with Parkinson's disease: a systematic review. Clin Rehabil 2005, 19(7):695-713.
31. Baram Y., Aharon-Peretz J., Simionotici Y., et al. Walking on virtual tiles. Neural Proc Lett 2002, 16:227-233.
32. Protero J. The treatment of akinesia using virtual images [MSc thesis 1993]. University of Washington College of Engineering; 1993.
33. Thaut M.H., McIntosh G.C., Rice R.R., et al. Rhythmic auditory stimulation in gait training for Parkinson's disease patients. Mov Disord 1996, 11(2):193-200.
34. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006, 5(8):677-687.
35. Stocchi F., Vacca L., Ruggieri S., et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005, 62(6):905-910.
36. Eggert K., Schrader C., Hahn M., et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008, 31(3):151-166.
37. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009, 24(7):993-1000.
38. Stocchi F., Vacca L., De Pandis M.F., et al. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci 2001, 22(1):93-94.
39. Poewe W.H., Rascol O., Quinn N., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6(6):513-520.
40. Giladi N., Boroojerdi B., Korczyn A.D., et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22(16):2398-2404.
41. Block G., Liss C., Reines S., et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997, 37(1):23-27.
42. Lopiano L., Rizzone M., Bergamasco B., et al. Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes. J Neurol Sci 2002, 195(2):167-170.
43. Deuschl G., Schade-Brittinger C., Krack P., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006, 355(9):896-908.
44. Kleiner-Fisman G., Herzog J., Fisman D.N., et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006, 21(Suppl 14):S290-S304.
45. Okun M.S., Fernandez H.H., Wu S.S., et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009, 65(5):586-595.
46. Hamani C., Stone S., Laxton A., et al. The pedunculopontine nucleus and movement disorders: anatomy and the role for deep brain stimulation. Parkinsonism Relat Disord 2007, 13(Suppl 3):S276-S280.
47. Stefani A., Lozano A.M., Peppe A., et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 2007, 130(Pt 6):1596-1607.
48. Moro E., Hamani C., Poon Y.Y., et al. Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain 2010, 133(Pt 1):215-224.
49. Kordower J.H., Freeman T.B., Snow B.J., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995, 332(17):1118-1124.
50. Olanow C.W., Goetz C.G., Kordower J.H., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003, 54(3):403-414.
51. Rodriguez-Gomez J.A., Lu J.Q., Velasco I., et al. Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells 2007, 25(4):918-928.